Plasmablastic lymphoma
MONDO:0017347An aggressive diffuse large B-cell lymphoma frequently arising in the setting of HIV infection and characterized by the presence of large neoplastic cells resembling B-immunoblasts which have the immunophenotypic profile of plasma cells. Sites of involvement include the oral cavity, sinonasal cavity, skin, soft tissues, gastrointestinal tract, and bone.
Also known as: PBL, Plasmablastic lymphoma, PLBL
2016 clinical trials for this condition and its sub-types, 20 tagged with Plasmablastic lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Gene therapy tackles HIV and lymphoma in one shot
Disease control OngoingThis early study tests whether giving gene therapy after standard chemotherapy is safe for people with AIDS-related non-Hodgkin lymphoma. The gene therapy adds anti-HIV genes to the patient's own blood stem cells, aiming to help the body fight HIV. Only 3 participants were enroll…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Immunotherapy drug tested for rare blood cancers
Disease control PausedThis study tests the drug pembrolizumab in people with certain aggressive lymphomas or rare histiocyte/dendritic cell cancers that have come back or not responded to treatment. The goal is to see if the drug can shrink tumors. The study is currently suspended and enrolled 18 part…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Gene therapy takes on HIV and cancer in one shot
Disease control OngoingThis early-phase trial tests a gene therapy approach for people with HIV who also have lymphoma that has returned or not responded to treatment. Researchers take the patient's own stem cells, add anti-HIV genes in the lab, and return them after a stem cell transplant. The goal is…
Phase 1/2 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Immunotherapy duo takes on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to treatment. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the combin…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Gene therapy trial aims to boost HIV fight in lymphoma patients
Disease control OngoingThis early-stage study tests whether giving gene therapy after chemotherapy is safe for people with AIDS-related non-Hodgkin lymphoma. The gene therapy adds special anti-HIV genes to the patient's own blood stem cells to help the body fight HIV. Ten participants will receive the …
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New combo tackles tough lymphoma in early trial
Disease control OngoingThis early-phase trial tests a new drug, loncastuximab tesirine, combined with a standard chemotherapy regimen (DA-EPOCH-R) in 11 adults with aggressive B-cell lymphomas. The main goal is to find the safest dose and check for side effects. It is not yet known if this combination …
Phase 1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC